FDA Grants Fast Track Status to Oral Orexin 2 Agonist Lu AH69593 for Narcolepsy

The U.S. Food and Drug Administration has granted Fast Track designation to Lundbeck’s investigational oral orexin 2 receptor (OX2R) agonist Lu AH69593 for the treatment of narcolepsy, marking a key regulatory milestone for the company’s emerging sleep-wake disorders pipeline.

The designation is intended to accelerate the development and regulatory review of therapies that address serious conditions with unmet medical needs. Lu AH69593 is currently being evaluated in a Phase 1b clinical program for patients with narcolepsy, a chronic neurological disorder characterized by impaired regulation of sleep and wakefulness.

Fast Track Designation Supports Development of a Novel Wake-Promoting Therapy

The FDA’s Fast Track program enables closer collaboration between regulators and developers through more frequent interactions, eligibility for rolling review, and the potential for priority review if qualifying criteria are met.

For Lundbeck, the designation strengthens the regulatory path for Lu AH69593, the company’s lead oral OX2R agonist and one of several investigational compounds targeting disorders associated with excessive daytime sleepiness.

Narcolepsy remains a significant unmet medical need despite the availability of symptomatic treatments. Many patients continue to experience excessive daytime sleepiness, sudden sleep attacks, fragmented nighttime sleep, sleep paralysis, hallucinations, and, in patients with narcolepsy type 1, cataplexy, a sudden loss of muscle tone often triggered by strong emotions. These symptoms can substantially impair education, employment, daily activities, and quality of life.

Targeting the Orexin Pathway to Restore Wakefulness

Lu AH69593 works by activating the orexin 2 receptor, a critical component of the brain’s wake-promoting network.

Orexin, also known as hypocretin, is a neuropeptide produced in the lateral hypothalamus that regulates arousal, wakefulness, and rapid eye movement (REM) sleep stability. Orexin-producing neurons project broadly throughout the brain, with OX2R playing a central role in maintaining sustained wakefulness.

Loss of orexin signaling is a defining biological feature of narcolepsy type 1, making restoration of this pathway an attractive therapeutic strategy. Unlike conventional therapies that primarily manage symptoms, OX2R agonists aim to directly address the underlying neurobiology responsible for excessive daytime sleepiness and disrupted sleep-wake regulation.

Phase 1b Program Evaluating Safety and Pharmacology

Lu AH69593 is currently undergoing Phase 1b clinical evaluation in patients with narcolepsy.

The ongoing study is assessing the investigational therapy’s safety, tolerability, pharmacokinetic, and pharmacodynamic profile. Lundbeck has not yet released efficacy data from the program.

The small-molecule candidate has not been approved by any regulatory authority worldwide, and its safety and clinical efficacy remain under investigation.

Executive Highlights Regulatory Progress

Johan Luthman, Executive Vice President and Head of Research & Development at Lundbeck, said the Fast Track designation represents an important milestone for both Lu AH69593 and the company’s broader neuroscience research strategy.

He noted that sustaining wakefulness affects nearly every aspect of daily life for people living with narcolepsy and said the FDA’s decision recognizes both the continuing unmet medical need and the therapeutic potential of orexin biology. Luthman added that the designation will enable closer engagement with the FDA as development progresses and reflects Lundbeck’s expanding pipeline across neurology, neuroendocrine disorders, and rare diseases.

Path Forward

With Fast Track designation now in place, Lundbeck will continue advancing the Phase 1b development program while working closely with the FDA on the clinical and regulatory pathway for Lu AH69593.

If future clinical studies demonstrate favorable safety and efficacy, the oral OX2R agonist could emerge as a differentiated treatment option that targets the biological mechanism underlying narcolepsy rather than solely managing its symptoms.

Reference

Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy – H. Lundbeck A/S